The development of delivery systems in experimental therapy usually requires "In vitro" release models, that should have specific characteristics including: low cost, simple procedure, high reproducibility and, very importantly, resemble as strictly as possible the "in vivo" behaviour.\ud Microparticles based on gelatine (GEM), or poly-lactide-co-glycolide (PEM) and colloidal lipid dispersions such as nanostructured lipid carriers (NLC) and cubosomes (CBS) represent good carriers for poorly water-soluble drugs. In particular bromocriptine (BC) has been successfully incorporated in micro and nanosystems. The release kinetics of bromocriptine from GEM, PEM, NLC and CBS have been determined by means of different experimental systems, such as a horizontal shaker method, a flow-through cell method, the reverse dialysis, the USP XXII paddle and the Franz cell methods. The influence of the experimental release method and of release media has been investigated
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.